The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease

Coronary Artery Disease

Volumn 8, Issue 11-12, 1997, Pages 677-682

  Rice, Gillian I ^a,b   Ossei Gerning, Nicholas ^a   Stickland, Max H ^a   Grant, Peter J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

IHD; Myocardial infarction; Paraoxonase

Indexed keywords

ARYLESTERASE; CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROMA; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENDER; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; SMOKING; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031434372     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199711000-00001     Document Type: Article

References (34)

1. Serrato M, Marian AJ: A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995, 96:3005-3008.
2. Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991, 88:1785-1792.
3. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320:915-924.
4. Steinberg D, Witztum JL: Lipoproteins and atherogenesis: current concepts. JAMA 1990, 264:3047-3051.
5. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, et al.: Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995, 91:2488-2496.
6. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, et al.: The yin and yang of oxidation in the development of the fatty streak. Arterioscler Thromb Vasc Biol 1996, 16:831-842.
7. Mackness MI, Durrington PN: HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995, 115:243-253.
8. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE: The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993, 3:73-76.
9. Blatter M-C, James RW, Messmer S, Barja F, Pometta D: Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Eur J Biochem 1993, 211:871-879.
10. Parthasarathy S, Barnett J, Fong LG: High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990, 1044:275-283.
11. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, et al.: Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995, 96:2882-2891.
12. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH: Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 1986, 32:671-673.
13. Szabó I, Róna K, Czinner A, Gachályi B, Káldor A: Is paraoxon hydrolytic activity in serum predictive of myocardial infarction? Clin Chem 1987; 33:742-743.
14. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, et al.: Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellltus. Atherosclerosis 1991, 86:193-199.
15. Blatter Garin M-C, Abbott C, Messmer S, Mackness M, Durrington P, Pometta D, et al.: Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J 1994, 304:549-554.
16. Abbott CA, Mackness MI, Kumur S, Boulton AJ, Durrington PN: Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995, 15:1812-1818.
17. Adkins S, Gan KN, Mody M, La Du BN: Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993, 52:598-608.
18. Ruiz J, Blanché H, James RW, Blatter Garin M-C, Vaisse C, Charpentier G, et al.: Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995, 346:869-872.
19. Odawara M, Tachi Y, Sasaki K, Tada K, Yamashita K: Gln192Arg polymorphism in paraoxonase gene is associated with coronary heart disease in Japanese NIDDM [abstract]. Diabetes 1996, 45 (suppl 2):65A.
20. Herrmann S-M, Blanc H, Poirier O, Arveiler D, Luc G, Evans A, et al.: The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis 1996, 126:299-303.
21. Antikainen M, Murtomäki S, Syvänne M, Pahlman R, Tahvanainen E, Jauhiainen M, et al.: The Gln-Arg 191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 1996, 98:883-885.
22. Nicoloso G, Hauert J, Kruithof EKO, Vaan Melle G, Bachmann F: Flbrinolysls in normal subjects - comparison between plasminogen activator inhibitor and other components of the fibrinolytic system. Thromb Haemost 1988, 59:299-303.
23. Sprengers ED, Kluft C: Plasminogen activator inhibitors. Blood 1987, 69:381-387.
24. Bosma J, van den Berg EA, Kooistra T, Siemieniak DR, Slightom JL: Human plasminogen activator inhibitor-1 gene. Promoter and structural gene nucleotide sequences. J Biol Chem 1988, 263:9129-9141.
25. Heywood DM, Ossei-Gerning N, Grant PJ: Association of Factor VII:C levels with environmental and genetic factors in patients with ischaemic heart disease and coronary atheroma characterised by angiography. Thromb Haemost 1996, 76:161-165.
26. Report of the Joint International Society and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical Nomenclature: Nomenclature and criteria for diagnosis of ischemic heart disease. Circulation 1979, 59:607-608.
27. Mansfield MW, Stickland MH, Carter A, Grant PJ: Polymorphisms of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes and in patients with diabetic retinopathy. Thromb Haemost 1994, 71:731-736.
28. Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ: Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol 1997, 17:33-37.
29. Hill WG: Estimation of linkage disequilibrium in randomly mating populations. Heredity 1974, 33:229-239.
30. Baumann RE, Henschen AH: Linkage disequilibrium relationships among four polymorphisms within the human fibrinogen gene cluster. Hum Genet 1994, 94:165-170.
31. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH: A prospective study of cholesterol, apolipoproteins, and the risk of myocardial Infarction. W Engl J Med 1991, 325:373-381.
32. Williams FM, Mutch E, Blain PG: Paraoxonase distribution in Caucasian males. Chem Biol Interactions 1993, 87:155-160.
33. Hegele RA, Brunt JH, Connelly PW: A polymorphism of the paraoxonase gene associated with variations in plasma-lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol 1995, 15:89-95.
34. Shih DM, Gu L, Hama S, Xia Y-R, Navab M, Fogelman AM, et al.: Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996, 97:1630-1639.